ENTXのチャート
ENTXの企業情報
| symbol | ENTx |
|---|---|
| 会社名 | Entera Bio Ltd （エンテラ・バイオ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Entera Bio Ltd is an Israel-based product-focused biotechnology company that specializes in the oral delivery of large molecules and biologics. The Company conducts clinical trials on its proprietary technology which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal (GI) tract. Entera Bio Ltd's technology addresses the major problems of oral drug delivery of large molecule active pharmaceutical ingredients (APIs). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. The Company’s proprietary technologies act synergistically to transport and protect large molecules. The Company develops drugs for hypoparathyroidism osteoporosis and bone healing. エンテラ・バイオはイスラエルのバイオ医薬品企業。有効な治療法が確立されていない疾患のための治療薬の発見、開発および商品化に焦点を当て事業を行う。主に副甲状腺機能低下症および骨粗しょう症の治療薬として経口カプセルの開発を手掛ける。主要製品候補には、副甲状腺ホルモンの治療薬EB612や、骨粗しょう症および癒着不能骨折の治療薬EB613などがある。 Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. |
| 本社所在地 | Kiryat Hadassah Minrav Building - Fifth Floor Jerusalem 9112002 ISR |
| 代表者氏名 | Gerald M. Lieberman ジェラルド・M・リーバーマン |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | ― |
| 設立年月日 | 40330 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.enterabio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/entx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -12.65700 |
| 終値（lastsale） | 5.85 |
| 時価総額（marketcap） | 66855672 |
| 時価総額 | 時価総額（百万ドル） 60.11296 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 88.47196 |
| 当期純利益 | 当期純利益（百万ドル） -10.02400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Entera Bio Ltd revenues was not reported. Net loss decreased 31% to $2.6M. Lower net loss reflects FV Adjustments of Financial Investments increase from $479K to $2.9M (income) GENERAL AND ADMINISTRATIVE EXPENSES (INC decrease of 70% to $854K (expense) Other financial expenses (income) net increase from $71K (expense) to $23K (income). |
ENTXのテクニカル分析
ENTXのニュース
Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613''s Potential Impact on Wednesday, September 28th @ 10am ET 2022/09/21 12:30:00 Benzinga
JERUSALEM, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX ), ("Entera" or the "Company"), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it will host a key opinion leader (KOL) webinar on the company''s lead asset EB613, and its potential impact on the osteoporosis market on Wednesday, September 28, 2022 at 10:00am ET. The webinar will feature presentations from KOLs John P. Bilezikian, MD, PhD, from Columbia University, Felicia Cosman, MD, also from Columbia University, and Bart L. Clarke, MD, from Mayo Clinic. The event will provide insight into the current treatment landscape and unmet medical need for post-menopausal women with osteoporosis. The discussion will focus on Entera Bio''s development of EB613, a proprietary formulation of PTH (1-34, teriparatide) as the first potential orally administered osteoanabolic treatment. Entera leadership will review their Phase 2 EB613 data, which will be followed by an overview of the Company''s proposed registrational Phase 3 plan submitted to FDA.
Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022/09/12 20:30:00 GlobeNewswire
JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins , today announced that the Company will present and host 1x1 meetings at the upcoming H.C. Wainwright 24 th Annual Global Investment Conference .
H.C. Wainwright Starts Entera Bio at Buy 2022/09/06 10:22:03 Investing.com
https://www.investing.com/news/pro/hc-wainwright-starts-entera-bio-at-buy-432SI-2886429
Entera Bio: Q2 Earnings Insights 2022/08/11 13:43:34 Benzinga
Entera Bio (NASDAQ: ENTX ) reported its Q2 earnings results on Thursday, August 11, 2022 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings Entera Bio beat estimated earnings by 31.25%, reporting an EPS of $-0.11 versus … Full story available on Benzinga.com
Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M 2022/08/11 12:59:00 Seeking Alpha
Entera Bio press release (ENTX): 1H GAAP EPS of -$0.24.Revenue of $0.11M (-59.3% Y/Y).Shares +3.68% PM
Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022/09/12 20:30:00 GlobeNewswire
JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins , today announced that the Company will present and host 1x1 meetings at the upcoming H.C. Wainwright 24 th Annual Global Investment Conference .
H.C. Wainwright Starts Entera Bio at Buy 2022/09/06 10:22:03 Investing.com
https://www.investing.com/news/pro/hc-wainwright-starts-entera-bio-at-buy-432SI-2886429
Entera Bio: Q2 Earnings Insights 2022/08/11 13:43:34 Benzinga
Entera Bio (NASDAQ: ENTX ) reported its Q2 earnings results on Thursday, August 11, 2022 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings Entera Bio beat estimated earnings by 31.25%, reporting an EPS of $-0.11 versus … Full story available on Benzinga.com
Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M 2022/08/11 12:59:00 Seeking Alpha
Entera Bio press release (ENTX): 1H GAAP EPS of -$0.24.Revenue of $0.11M (-59.3% Y/Y).Shares +3.68% PM
Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022 2022/08/11 10:30:00 GlobeNewswire
JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial and operating results for the quarter ended June 30, 2022.
Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO 2022/07/18 13:11:36 Benzinga
Following its End of Phase 2 Meeting with the FDA, Entera Bio Ltd (NASDAQ: ENTX ) has designed the pivotal study for EB613 as an 18-month double-blind placebo-controlled study, followed by a 6-month open-label transition to alendronate for all patients. The study''s primary endpoint employs the Foundation for the National Institutes of Health Bone Quality Program (FNIH BQP) total hip Bone Mineral Density (BMD) as a surrogate endpoint … Full story available on Benzinga.com
Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company’s President of Research & Development to Pursue Outside Opportunities 2022/06/17 21:00:00 GlobeNewswire
BOSTON and JERUSALEM, June 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Dr. Phillip Schwartz, the Company’s President of Research & Development and Founder, will resign from his current role effective July 21, 2022 to pursue other opportunities. Dr. Schwartz also stepped down from the Company’s Board of Directors, effective June 15, 2022. Dr. Schwartz’s resignation was not a result of any disagreement with the Company and Dr. Schwartz will remain as a consultant to the Company.
Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company''s President of Research & Development to Pursue Outside Opportunities 2022/06/17 21:00:00 Benzinga
BOSTON and JERUSALEM, June 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX ), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Dr. Phillip Schwartz, the Company''s President of Research & Development and Founder, will resign from his current role effective July 21, 2022 to pursue other opportunities. Dr. Schwartz also stepped down from the Company''s Board of Directors, effective June 15, 2022. Dr. Schwartz''s resignation was not a result of any disagreement with the Company and Dr. Schwartz will remain as a consultant to the Company. Bringing in his expertise from various development and commercialization roles at Merck KGaA-Serono and Endo Pharmaceuticals, Dr. Schwartz was a co-founder of Entera Bio in 2009 and led the Company as Chief Executive Officer through 2019 and its IPO in 2018. "We are grateful for Phillip''s vision and leadership which have been paramount to the progression of Entera from an early stage R&D platform to a late stage clinical company with two core PTH programs in Phase 2/3 development and core R&D strategic partnerships, including with Amgen," said Mr.
Entera Bio Ltd. (ENTX) CEO Spiros Jamas on Q1 2022 Results - Earnings Call Transcript 2022/05/18 18:34:07 Seeking Alpha
Entera Bio Ltd. (NASDAQ:NASDAQ:ENTX) Q1 2022 Earnings Conference Call May 17, 2022 08:00 ET Company Participants Spiros Jamas - Chief Executive Officer Miranda Toledano - Chief Business…